ID   A549 DHODH-/-
AC   CVCL_YZ46
SY   DHODH-/- A549
DR   cancercelllines; CVCL_YZ46
DR   Wikidata; Q98125454
RX   PubMed=32754890;
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 2867; DHODH.
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 05-10-23; Version: 6
//
RX   PubMed=32754890; DOI=10.1007/s13238-020-00768-w;
RA   Xiong R., Zhang L.-K., Li S.-L., Sun Y., Ding M.-Y., Wang Y., Zhao Y.-L.,
RA   Wu Y., Shang W.-J., Jiang X.-M., Shan J.-W., Shen Z.-H., Tong Y.,
RA   Xu L.-X., Chen Y., Liu Y.-L., Zou G., Lavillete D., Zhao Z.-J., Wang R.,
RA   Zhu L.-L., Xiao G.-F., Lan K., Li H.-L., Xu K.;
RT   "Novel and potent inhibitors targeting DHODH are broad-spectrum
RT   antivirals against RNA viruses including newly-emerged coronavirus
RT   SARS-CoV-2.";
RL   Protein Cell 11:723-739(2020).
//